The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

ISA 2022

The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
View all videos

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter